CJC-1295 and Ipamorelin Dosage: The Classic Stack
CJC-1295 and ipamorelin are the most commonly paired growth hormone peptides in research. This guide explains why they are combined and collects the dosing ranges into a reference chart. Figures are research-reported and not dosing advice.
Why the pair works together
CJC-1295 is a GHRH analog and ipamorelin is a ghrelin receptor agonist. They stimulate growth hormone release through two different pathways, so combining them is studied for a stronger and more natural pulse than either peptide alone. Ipamorelin is also selective, meaning it triggers little cortisol or prolactin release, which is part of its appeal.
Research-reported dosing chart
| Peptide | Reported per-dose range | Frequency |
|---|---|---|
| CJC-1295 (no DAC) | 100 mcg | 1 to 3 times daily |
| Ipamorelin | 100 to 300 mcg | 1 to 3 times daily |
| Combined dose | 100 mcg + 100 to 200 mcg | Often before bed and post-fast |
A common approach is 100 mcg of each, taken together, once to three times per day, with at least one dose at night. Convert these micrograms into syringe units with the dosage calculator.
DAC vs no DAC
CJC-1295 comes with or without a drug affinity complex (DAC). The DAC version has a much longer half-life and is dosed less often, while the no-DAC version is short acting and pairs naturally with ipamorelin for daily pulsing. The CJC-1295 protocol page covers the difference in detail.
Accuracy and safety
Measure each peptide separately unless using a pre-mixed blend. Review the CJC-1295 side effects and read the ipamorelin protocol before combining.